Dermsquared Scheduled Maintenance, Thursday Feb 29, 6:30am to 8:30am EST

On-Demand CME Videos

Take the Challenge to Manage Moderate-to-Severe Psoriasis From Head-to-Toe: CME Satellite Symposium - Online CME Activity

About

What site is associated with the greatest risk for the development of psoriatic arthritis?
a. scalp
b. palms
c. nails
d. genitals
e. legs

To find out the answer, click below to start the activity!

This activity is supported by an educational grant from Lilly.

Availability

In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

July 18, 2023

Expiration Date:

July 18, 2024

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Identify the relationship between psoriasis, psoriatic arthritis and biologics

  • Describe the role of IL-17 inhibitors for the management of moderate-to-severe plaque psoriasis in challenging body areas such as, nails, scalp, genitals, palms, and soles of the feet

  • Recognize patients who would benefit from IL-17 inhibitors for the management of moderate-to-severe plaque psoriasis in challenging body areas

  • Discuss how PAs and NPs can work in a multidisciplinary team to manage patients with moderate-to-severe plaque psoriasis in challenging body areas

Intended Audience

This activity has been designed for dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.

Faculty
Brad
Brad Glick, DO, MPH

Program Director, Dermatology Residency
Larkin Community Hospital Palm Springs Campus
Hialeah, FL

Benjamin
Benjamin Lockshin, MD

EVP of Strategic Initiatives
Director of the Clinical Trials Center
Assistant Professor
US Dermatology Partners
Georgetown University
Rockville, MD

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Brad P. Glick, DO, MPH

Ownership interest: Top MD stock

Benjamin Lockshin, MD

Grant/Research Support: Abbvie, Eli Lilly, Celgene, Regeneron, Sanofi Genzyme, DermTech, Exact Sciences, Pfizer, Leo, Arcutis, Dermavant 

Consultant: AbbVie, Eli Lilly, Regeneron, Sanofi Genzyme, DermTech, Exact Sciences, Dermavant, Arcutis, Leo 

Speakers’ Bureau or Honoraria: Abbvie, Eli Lilly, Regeneron, Sanofi Genzyme, Dermavant, Arcutis, Leo

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved